Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy PhaseBio Pharmaceuticals stock (PHAS)

Buy PhaseBio Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

PhaseBio Pharmaceuticals is a biotechnology & medical research business based in the US. PhaseBio Pharmaceuticals shares (PHAS) are listed on the NASDAQ and all prices are listed in US Dollars. PhaseBio Pharmaceuticals employs 60 staff and has a trailing 12-month revenue of around $818,000.

Our top picks for where to buy PhaseBio Pharmaceuticals stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

Alternative pick for crypto trading

Go to site
  • $0 commission trading
  • Instant withdrawals with a 1.75% fee
  • Supports 250+ cryptocurrencies
  • High-yield account earns up to 4.65% APY
Terms apply. Cryptoassets are highly volatile. Your capital is at risk. Available in the US, CA, UK and AU

Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.

How to buy PhaseBio Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – PHAS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy PhaseBio Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

PhaseBio Pharmaceuticals stock price (NASDAQ: PHAS)

Use our graph to track the performance of PHAS stocks over time.

PhaseBio Pharmaceuticals shares at a glance

Information last updated 2023-02-26.
52-week range$0.00 - $0.00
50-day moving average $0.43
200-day moving average $0.91
Wall St. target price$1.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.38

Is it a good time to buy PhaseBio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PhaseBio Pharmaceuticals financials

Revenue TTM $818,000
Gross profit TTM $-91,276,000
Return on assets TTM -106.07%
Return on equity TTM -3091.02%
Profit margin 0%
Book value $-2.36
Market Capitalization $3.5 million

TTM: trailing 12 months

PhaseBio Pharmaceuticals share dividends

We're not expecting PhaseBio Pharmaceuticals to pay a dividend over the next 12 months.

PhaseBio Pharmaceuticals share price volatility

Over the last 12 months, PhaseBio Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PhaseBio Pharmaceuticals's is 2.8691. This would suggest that PhaseBio Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

PhaseBio Pharmaceuticals overview

PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc.

Frequently asked questions

What percentage of PhaseBio Pharmaceuticals is owned by insiders or institutions?
Currently 6.721% of PhaseBio Pharmaceuticals shares are held by insiders and 55.205% by institutions.
How many people work for PhaseBio Pharmaceuticals?
Latest data suggests 60 work at PhaseBio Pharmaceuticals.
When does the fiscal year end for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals's fiscal year ends in December.
Where is PhaseBio Pharmaceuticals based?
PhaseBio Pharmaceuticals's address is: 1 Great Valley Parkway, Malvern, PA, United States, 19355
What is PhaseBio Pharmaceuticals's ISIN number?
PhaseBio Pharmaceuticals's international securities identification number is: US7172241090
What is PhaseBio Pharmaceuticals's CUSIP number?
PhaseBio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 717224109

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site